Back to Journals » International Journal of Nanomedicine » Volume 15

Size-Dependent Cytotoxicity of Hydroxyapatite Crystals on Renal Epithelial Cells

Authors Sun XY, Chen JY, Rao CY, Ouyang JM

Received 30 September 2019

Accepted for publication 9 June 2020

Published 15 July 2020 Volume 2020:15 Pages 5043—5060

DOI https://doi.org/10.2147/IJN.S232926

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Linlin Sun


Xin-Yuan Sun, Jia-Yun Chen, Chen-Ying Rao, Jian-Ming Ouyang

Department of Chemistry, Institute of Biomineralization and Lithiasis Research, Jinan University, Guangzhou 510632, People’s Republic of China

Correspondence: Jian-Ming Ouyang
Department of Chemistry Institute of Biomineralization and Lithiasis Research,Jinan University, Guangzhou 510632, People’s Republic of China
Tel +86 20-85223353
Email toyjm@jnu.edu.cn

Background: Hydroxyapatite (HAP) is a common component of most idiopathic calcium oxalate (CaOx) stones and is often used as a nidus to induce the formation of CaOx kidney stones.
Methods: This work comparatively studies the cytotoxicity of four kinds of HAP crystals with different sizes (40 nm to 2 μm), namely, HAP-40 nm, HAP-70 nm, HAP-1 μm, and HAP-2 μm, on human renal proximal tubular epithelial cells (HK-2).
Results: HAP crystals reduce the viability and membrane integrity of HK-2 cells in a concentration-dependent manner and consequently cause cytoskeleton damage, cell swelling, increased intracellular reactive oxygen species level, decreased mitochondrial membrane potential, increased intracellular calcium concentration, blocked cell cycle and stagnation in G0/G1 phase, and increased cell necrosis rate. HAP toxicity to HK-2 cells increases with a decrease in crystal size.
Conclusion: Cell damage caused by HAP crystals increases the risk of kidney stone formation.

Keywords: cytotoxicity, nanocrystal, hydroxyapatite, crystal size, cell injury

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]